Wednesday, September 13, 2017 11:32:24 AM
Mymetics to Present New Preclinical Data on Thermostable and Cold-Chain Independent Virosome based Vaccines
The new preclinical data will be presented at three upcoming events.
12 – 14 September, 2017: Modern Vaccines Adjuvants & Delivery Systems, Porto, Portugal.
16 – 18 September, 2017: ILS Liposome Advances & Liposome Research, Athens, Greece.
10 – 12 October, 2017: World Vaccine Congress Europe, Barcelona, Spain.
The preliminary results are showing that spray drying and lyophilization may conserve the virosome structure and antigens during the manufacturing process. Preclinical studies showed that Mymetics HIV-1 vaccine candidate, after being downstream processed into different powder solid dosage forms, could trigger specific antibodies, which were variable depending on the formulation. Antibodies were quantified in serum, nasal washes, vaginal washes and feces by the immuno-PCR Imperacer® assays.
https://www.otcmarkets.com/stock/MYMX/news/Mymetics-to-Present-New-Preclinical-Data-on-Thermostable-and-Cold-Chain-Independent-Virosome-based-Vaccines?id=169649&b=y
The new preclinical data will be presented at three upcoming events.
12 – 14 September, 2017: Modern Vaccines Adjuvants & Delivery Systems, Porto, Portugal.
16 – 18 September, 2017: ILS Liposome Advances & Liposome Research, Athens, Greece.
10 – 12 October, 2017: World Vaccine Congress Europe, Barcelona, Spain.
The preliminary results are showing that spray drying and lyophilization may conserve the virosome structure and antigens during the manufacturing process. Preclinical studies showed that Mymetics HIV-1 vaccine candidate, after being downstream processed into different powder solid dosage forms, could trigger specific antibodies, which were variable depending on the formulation. Antibodies were quantified in serum, nasal washes, vaginal washes and feces by the immuno-PCR Imperacer® assays.
https://www.otcmarkets.com/stock/MYMX/news/Mymetics-to-Present-New-Preclinical-Data-on-Thermostable-and-Cold-Chain-Independent-Virosome-based-Vaccines?id=169649&b=y
Recent GSK News
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 05/26/2026 02:23:47 PM
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 05/26/2026 02:17:14 PM
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 05/22/2026 11:19:14 AM
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 05/20/2026 02:40:41 PM
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 05/19/2026 03:01:09 PM
- B7-H3 Becomes The Hottest Antigen In Oncology, And One NK Engager Enters Clinic • PR Newswire (Canada) • 05/18/2026 06:22:00 PM
- B7-H3 Becomes The Hottest Antigen In Oncology, And One NK Engager Enters Clinic • PR Newswire (US) • 05/18/2026 06:22:00 PM
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 05/18/2026 03:03:41 PM
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 05/18/2026 10:29:35 AM
- Form 13F-HR - Quarterly report filed by institutional managers, Holdings • Edgar (US Regulatory) • 05/14/2026 08:45:58 PM
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 05/14/2026 04:22:53 PM
- Julie Bowen and Ty Burrell team up with GSK to raise awareness about meningitis risks for teens and young adults • Business Wire • 05/07/2026 12:00:00 PM
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 05/06/2026 05:52:25 PM
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 05/05/2026 04:54:26 PM
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 05/01/2026 03:11:25 PM
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 05/01/2026 03:08:31 PM
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 04/29/2026 04:00:42 PM
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 04/29/2026 12:09:42 PM
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 03/31/2026 10:16:09 AM
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 03/27/2026 11:43:56 AM
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 03/27/2026 11:37:58 AM
- GSK’s RSV Vaccine, AREXVY, Approved in US for Expanded Age Indication in Adults Aged 18–49 Years at Increased Risk • Business Wire • 03/13/2026 03:44:00 PM
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 03/12/2026 05:15:24 PM
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 03/12/2026 12:25:14 PM
